Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction

• Published in: Journal of clinical medicine 2021-04, Vol.10 (9), p.1819
• Main Authors: Haberman, Dan, Estévez-Loureiro, Rodrigo, Benito-Gonzalez, Tomas, Denti, Paolo, Arzamendi, Dabit, Adamo, Marianna, Freixa, Xavier, Nombela-Franco, Luis, Villablanca, Pedro, Krivoshei, Lian, Fam, Neil, Spargias, Konstantinos, Czarnecki, Andrew, Pascual, Isaac, Praz, Fabien, Sudarsky, Doron, Kerner, Arthur, Ninios, Vlasis, Gennari, Marco, Beeri, Ronen, Perl, Leor, Danenberg, Haim, Poles, Lion, Shimoni, Sara, Goland, Sorel, Caneiro-Queija, Berenice, Scianna, Salvatore, Moaraf, Igal, Schiavi, Davide, Scardino, Claudia, Corpataux, Noé, Echarte-Morales, Julio, Chrissoheris, Michael, Fernández-Peregrina, Estefanía, Di Pasquale, Mattia, Regueiro, Ander, Vergara-Uzcategui, Carlos, Iñiguez-Romo, Andres, Fernández-Vázquez, Felipe, Dvir, Danny, Taramasso, Maurizio, Shuvy, Mony
• Format: Article
• Language: English
• Subjects: Clinical medicine; Clinical outcomes; Ejection fraction; Heart attacks; Heart failure; Hemodynamics; Mortality; Normal distribution; Patients; Pulmonary arteries; Success; Veins & arteries
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10091819

Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased risk of mortality. Transcatheter mitral valve repair may therefore be a suitable therapy. However, data on clinical outcomes of patients in an acute setting are scarce, especially those with reduced left ventricle (LV) dysfunction. We conducted a multinational, collaborative data analysis from 21 centers for patients who were, within 90 days of acute MI, treated with MitraClip due to severe MR. The cohort was divided according to median left ventricle ejection fraction (LVEF)-35%. Included in the study were 105 patients. The mean age was 71 ± 10 years. Patients in the LVEF < 35% group were younger but with comparable Euroscore II, multivessel coronary artery disease, prior MI and coronary artery bypass graft surgery. Procedure time was comparable and acute success rate was high in both groups (94% vs. 90%, = 0.728). MR grade was significantly reduced in both groups along with an immediate reduction in left atrial V-wave, pulmonary artery pressure and improvement in New York Heart Association (NYHA) class. In-hospital and 1-year mortality rates were not significantly different between the two groups (11% vs. 7%, = 0.51 and 19% vs. 12%, = 0.49) and neither was the 3-month re-hospitalization rate. In conclusion, MitraClip intervention in patients with acute severe functional mitral regurgitation (FMR) due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.